ONCOLOGY TIMES, 2021, January
INDIANAPOLIS, Indiana—A non-randomized 36-patient phase-two clinical study found a big reduction in acute graft-versus-host disease (GVHD) after adding the dipeptidyl peptidase-4 (DPP-4, also known as CD26) inhibitor sitagliptin (long established as an anti-glycemic agent for treating type-2 diabetes) to immunosuppression therapy for allogeneic stem-cell transplantation.
“Impressively we found a very low rate of grade two to four acute graft versus host disease. Of the 36 patients we had only two patients who developed acute graft versus host disease by day 100. One had grade two, one had grade four,” said Sherif S. Farag MD PHD, Director of the Stem Cell Transplant and Cellular Therapy Program at Indiana University School of Medicine’s Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, after publication of his group’s report in the New England Journal of Medicine.